Legal uncertainty outweighs positives from J&J results

16 July 2019

The share price of Johnson & Johnson (NYSE: JNJ), the first of the pharma majors to report this quarter's financials, was down by more than 1% at lunchtime on Tuesday after the US healthcare giant announced its financial results for the second quarter of 2019.

Better-than-anticipated earnings and the issuing of improved sales guidance for 2019 might have been expected to deliver a stock market boost, but the volume of lawsuits involving alleged cancer-causing talcum powder and J&J’s marketing of opioids continue to cause uncertainty.

Sales across the group were $2.06 billion during the quarter, down 1.3% on the same period in 2018, though they were up 4% when excluding acquisitions and divestitures on an operational basis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK